Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer

Similar Items

• Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy
  od: Rangachari, Deepa, i dr.
  Izdano: (2017)
• Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR‐G719A and Other Uncommon EGFR Mutations
  od: Sehgal, Kartik, i dr.
  Izdano: (2020)
• Comparative analysis of alectinib and brigatinib in real-world treatment of advanced NSCLC with ALK rearrangements
  od: Kyuhwan Kim, i dr.
  Izdano: (2025-02-01)
• De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers
  od: Lucena-Araujo, Antonio R., i dr.
  Izdano: (2016)
• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  od: Rangachari, Deepa, i dr.
  Izdano: (2017)